<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200210</url>
  </required_header>
  <id_info>
    <org_study_id>LUMINA</org_study_id>
    <nct_id>NCT03200210</nct_id>
  </id_info>
  <brief_title>Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients</brief_title>
  <acronym>LUMINA</acronym>
  <official_title>Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double-Blinded, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will enroll continuous ambulatory peritoneal dialysis (CAPD) patients with&#xD;
      hyperuricemia and randomly divide them into two groups, treated with Febuxostat and placebo&#xD;
      respectively. After 3 years of following up, cardiovascular events, all cause mortality,&#xD;
      cardiovascular mortality and non-fatal cardiovascular events are collected and recorded. The&#xD;
      difference of cardiovascular events, all cause mortality and non-fatal cardiovascular event&#xD;
      rate will be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators anticipate enrolling 548 CAPD patients who have hyperuricemia in 21 centers&#xD;
      and randomly allocate them into Febuxostat treatment group and placebo group. This study is&#xD;
      double-blinded and will be followed up for 3 years. The primary endpoint is cardiovascular&#xD;
      events, secondary endpoints are all-cause mortality, cardiovascular mortality and non-fatal&#xD;
      cardiovascular events separately. All the endpoints will be collected, as well as other&#xD;
      outcomes, such as blood pressure and dialysis dose and so on. The outcomes will be analyzed&#xD;
      using statistics software.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiovascular events compose of cardiovascular mortality and non-fatal cardiovascular events, cardiovascular mortality includes acute myocardial infarction, fatal arrhythmia, sudden death, cardiomyopathy, heart failure, and stroke; non-fatal cardiovascular events includes non-fatal acute myocardial infarction, hospital admission of heart failure, unstable angina, atherosclerotic disease needed hospitalization (including aneurysm, arterial dissection, arteriosclerosis occlusion), non-fatal stroke, transient ischaemic attack or lower limb ischaemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>3 years</time_frame>
    <description>To record and calculate the deaths caused by any cause during follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>3 years</time_frame>
    <description>To record and calculate the deaths cardiovascular mortality includes acute myocardial infarction, fatal arrhythmia, sudden death, cardiomyopathy, heart failure, and stroke during follow up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal cardiovascular events</measure>
    <time_frame>3 years</time_frame>
    <description>To record and calculate the non-fatal cardiovascular events including non-fatal acute myocardial infarction, hospital admission of heart failure, unstable angina, atherosclerotic disease needed hospitalization (including aneurysm, arterial dissection, arteriosclerosis occlusion), non-fatal stroke, transient ischaemic attack or lower limb ischaemia during follow up period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">548</enrollment>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Treatment with Febuxostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat, starting at dose 20mg/d, once a day. And adjust dose according to serum uric acid at specific visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Same dose and dose adjustment as the intervention arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat tablets would be given to patients at dose of 20mg/d, once a day, and dose would be adjusted according to serum uric acid at specific visits.</description>
    <arm_group_label>Treatment with Febuxostat</arm_group_label>
    <other_name>Febuxostat Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pills manufactured to mimic Febuxostat tablets</description>
    <arm_group_label>Treatment with placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Subjects who are able to understand and have voluntarily signed the informed consent&#xD;
             form (ICF)&#xD;
&#xD;
          -  18-70 years old at the time of randomization&#xD;
&#xD;
          -  Subjects on PD for more than 3 months.&#xD;
&#xD;
          -  Subjects have hyperuricemia, women: 6mg/dl(360μmol/L) &lt;serum uric acid&#xD;
             (sUA)&lt;12mg/dl(720μmol/L); men: 7mg/dl(420μmol/L)&lt;sUA&lt;12mg/dl(720μmol/L).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Subjects has history of gout&#xD;
&#xD;
          -  Subjects who have a myocardial infarction, unstable angina,cardiovascular&#xD;
             reconstructive surgery (such as a stent or bypass surgery), cerebrovascular accident&#xD;
             12 weeks prior to randomization, or plan cardiovascular reconstructive surgery during&#xD;
             the trial&#xD;
&#xD;
          -  Subjects who have New York stage IV heart failure occurs 4 weeks prior to the&#xD;
             screening&#xD;
&#xD;
          -  Subjects who have previously received renal transplantation and are currently&#xD;
             prescribed immunosuppressive therapy&#xD;
&#xD;
          -  Subjects who have severe liver disease, such as acute hepatitis, chronic active&#xD;
             hepatitis, cirrhosis&#xD;
&#xD;
          -  Subjects who have alanine aminotransferase (ALT) greater than 2 folds of the upper&#xD;
             limited of normal or total bilirubin greater than 1.5 folds of upper limited of normal&#xD;
&#xD;
          -  Subjects who have severe infections 4 weeks prior to the screening, such as pneumonia&#xD;
             and peritoneal dialysis-related peritonitis;&#xD;
&#xD;
          -  Subjects who have a major surgery 12 weeks prior to screening or not yet fully&#xD;
             recovered from the surgery&#xD;
&#xD;
          -  Subjects who have a malignancy&#xD;
&#xD;
          -  Subjects who report a history of illicit drug use or a regular or daily alcohol&#xD;
             consumption of≥4 alcoholic drinks per day in the 2 years before Screening&#xD;
&#xD;
          -  Subjects who are allergic to Febuxostat&#xD;
&#xD;
          -  Subjects who are enrolled in other clinical studies within 4 weeks or currently at&#xD;
             randomization&#xD;
&#xD;
          -  Subjects who are currently taking mercaptopurine, azathioprine, vidarabine, didanosine&#xD;
&#xD;
          -  Subjects who are taking losartan, fenofibrate, thiazide diuretics or loop diuretics&#xD;
             within 4 weeks at randomization&#xD;
&#xD;
          -  Subjects who require long-term use of steroids (prednisone &lt;30mg / d, or equivalent&#xD;
             amount of other steroids and the use of &lt;2 weeks can be enrolled)&#xD;
&#xD;
          -  Subjects who require long-term use of salicylic acid drugs except low-dose aspirin&#xD;
&#xD;
          -  Fertility, lactation patients unwilling or unable to contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xueqing Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xueqing Yu, MD, PhD</last_name>
    <phone>8620-87766335</phone>
    <email>yuxq@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueqing Yu, M.D. &amp; Ph.D</last_name>
      <phone>8620-8776633</phone>
      <email>yuxq@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yu</last_name>
    </contact_backup>
    <investigator>
      <last_name>Xueqing Yu, M.D. &amp; Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 25, 2017</study_first_submitted>
  <study_first_submitted_qc>June 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xue Qing Yu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Continuous Ambulatory Peritoneal Dialysis (CAPD)</keyword>
  <keyword>Hyperuricemia</keyword>
  <keyword>Cardiovascular events</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

